Kornimate/medical-research-clean huggingface dataset:
efficacy of topical apraclonidine for the treatment of ocular synkinesis

Conditions: Synkinesis; Facial Nerve Palsy

Summary: the purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the uab facial nerve clinic.

uab has a large facial nerve clinic that treats patients with acquired facial nerve palsies and the associated difficulties of swallowing/speaking, and visual field defects from ptosis (a drooping or falling of the upper eyelid) and synkinesis (unwanted contractions of the muscles of the face during attempted movement.). commonly, patients will experience involuntary eyelid contraction with oral movements like smiling. for eyelid synkinesis causing significant aesthetic or functional difficulty, surgery or botox is often the first line treatment. however, not all patients desire this, and some are poor surgical candidates due to other comorbidities. botox has been shown to work well for these patients, but can be only partially effective. in addition, patients experience a wearing off period between treatments. several eye drops are available for the medical treatment of ptosis, including apraclonidine and 0.1% oxymetazoline. both are alpha 2 adrenergic agonists, which stimulates mullers muscle, causing muscle contraction and upper eyelid lifting. in addition, apraclonidine has been shown to be beneficial in patients with blepharospasm in a pilot study by vijayakumar et. al. we hypothesize that patients with synkinesis, similar to patients with ptosis and blepharospasm, could have symptomatic improvement with apraclonidine use. our study will initially be a pilot study, designed similarly to the vijayakumar study. if this shows improvement for these patients, our hope is to pursue a randomized control trial.

Eligibility criteria:
inclusion criteria: * age 18 years or older * ability to speak and comprehend english * ability to consent for themselves * diagnosis of synkinesis affecting eye movement exclusion criteria: * age less than 18 years * unable to speak and comprehend english * unable to consent for themselves * diagnosis of congenital ptosis, horner syndrome, myasthenia travis, mechanical ptosis * visual field loss from causes unrelated to facial nerve injury * currently receiving monoamine oxidase inhibitors * known hypersensitivity to apraclonidine or other components of the drug under study
handwriting rehabilitation in parkinson disease

Conditions: Parkinson Disease; Neurorehabilitation; Handwriting

Summary: the aim of the study is to evaluate the efficacy of an intensive handwriting treatment in parkinson's disease.

the investigators aimed to understand whether an intensive handwriting treatment with cognitive engagement is more effective than a treatment exploiting only the passive wrist joint mobilization in parkinson's disease.

Eligibility criteria:
inclusion criteria: * parkinson's disease patients exclusion criteria: * mini mental state examination (mmse) score \< 24 * left handed subjects * subjects with dyskinesias * subjects with deep brain stimulation
a study of bgc515 capsules in subjects with advanced solid tumors

Conditions: Mesothelioma; Epithelioid Hemangioendothelioma(EHE); Solid Tumor

Summary: the goal of this open-label, dose escalation and dose expansion phase i clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of bgc515 administered once daily in 3 weeks cycles in solid tumor patients.


Eligibility criteria:
inclusion criteria: * having signed the written informed consent form * male or female aged ≥18 years * life expectancy ≥12 weeks * eastern cooperative oncology group (ecog) performance score 0 or 1 * dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic mesothelioma (mm), epithelioid hemangioendothelioma (ehe), or other advanced solid tumors who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care * dose expansion phase: histologically or cytologically confirmed locally advanced or metastatic mm, ehe, etc. regardless of hippo signaling pathway abnormalities, or other advanced solid tumors with hippo signaling pathway abnormalities, who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care * at least one measurable lesion exclusion criteria: * previous or current use of transcriptional enhanced associate domain (tead) inhibitors * inadequate wash-out of prior therapies described per protocol * patients with severe or unstable systemic disease, unstable or symptomatic central nervous system (cns) metastasis * clinically significant cardiovascular disease as defined in the protocol * women who are pregnant or breastfeeding * hypersensitivity to the active pharmaceutical ingredient or any excipient of bgc515 * study staff member or relative of a study staff member directly related to this clinical trial, or a subordinate of the investigator in this trial or an employee of the sponsor, though not directly related to this trial * serious systemic diseases or laboratory abnormalities or other conditions that, at the investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.
a project to improve the diagnosis and prognosis of myocardial injury associated to non cardiac surgery

Conditions: Myocardium; Injury

Summary: major adverse cardiovascular events are the leading cause of perioperative morbimortality in non-cardiac surgery. perioperative myocardial infarction is usually asymptomatic, with a mortality around 10-12%. myocardial injury in noncardiac surgery (mins), is defined as a myocardial injury that provokes a troponin increase due to myocardial ischemia. mins is a predictor of morbimortality at short term and at long term. the aim of the study is to improve the diagnosis of myocardial injury after non cardiac surgery in high-risk patients, improve its treatment in case of mins and establish prevention strategies.


Eligibility criteria:
inclusion criteria: * patients of both genders over 45 years scheduled for non-urgent surgery with in-hospital stay of 24 hours minimum who require general and or regional anaesthesia (epidural or subarachnoidal) that have signed the inform consent who will be operated of: 1. high-risk surgery: * open abdominal aortic aneurism repair * major vascular surgery * major amputations * carotid endarterectomy * duodeno-pancreatic surgery * hepatic resection or resection of biliary duct * esophagectomy * suprarenal resection * cystectomy * pneumonectomy 2. medium risk-surgery with cardiovascular risk factors (see below): * intraperitoneal surgery (rectum, colon, small bowel, gastric surgery) * peripherical angioplasty * endovascular aneurism repair * head and neck surgery * major orthopedic surgery (hip, knee, column) * major urological or gynecological surgery * thoracic surgery (lobectomy or atypical pulmonary resections) a) with 1 risk factor: * history of coronary artery disease * history of cerebrovascular disease (history of transient ischemic attack or stroke) * history of congestive heart failure * history of vascular disease b) with 2 risk factors: * diabetes mellitus with medical treatment * renal disease (fge \< 45 ml•min-1•1.73m2 ) * functional capacity \< 4mets * intraoperative blood loss \>600ml exclusion criteria: * patients without consent information * patients non included in the inclusion criteria
optimizing miltefosine treatment for cutaneous leishmaniasis patients

Conditions: Cutaneous Leishmaniases

Summary: while there are indications that 28 days of miltefosine is not sufficient for treating cl by l. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking. in this study, longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics. this data will be crucial to provide more information on duration and dosing of miltefosine in cl patients globally, and in ethiopia and pediatric patients in particular.

in this project, parasite dynamics and miltefosine pharmacokinetics in the skin and blood during routine durations of miltefosine treatment (4-8 weeks) are studied with the aim to provide evidence to optimize miltefosine dosing for treatment of cl. by also studying these factors in children who get allometric miltefosine dosing, data which can be used to adapt the current allometric dosing scheme specifically to children with cl will be produced. exploratory objectives will look into searching for more objective outcome assessment measures, resistance, helminth infection and nutritional status as potential factors affecting treatment response.

Eligibility criteria:
inclusion criteria: * clinical or parasitological (microscopy or pcr) confirmation of leishmaniasis * age \>2 * clinical decision to start miltefosine treatment as systemic treatment * in case of females of child-bearing age: willing to take contraceptive for 6 months (parenteral or iud or implant) * willing and able to provide informed consent * willing to be hospitalized for the duration of treatment exclusion criteria: * currently on treatment or having received modern treatment for leishmaniasis in the last 3 months * pregnant (pregnancy test at d0) or breastfeeding * unlikely to come for follow-up visits * abnormal lab values hemoglobin \ 3x upper normal range creatinine above the normal limit
exploring the influence of clinical factors on the prognosis of papillary renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: patients with renal cell carcinoma who were admitted to the first affiliated hospital of sun yat-sen university from february 1, 2021, to february 1, 2022, and met the following inclusion and exclusion criteria were collected. clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this. (inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of prcc,b: age 18 years or older, c: localized rcc underwent radical nephrectomy or partial nephrectomy in our center. exclusion criteria:a: lack of original ct images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)


Eligibility criteria:
inclusion criteria: a: pathology of the surgical specimen confirmed the diagnosis of prcc,b: age 18 years or older, c: localized rcc underwent radical nephrectomy or partial nephrectomy in our center exclusion criteria: a: lack of original ct images, b: patients with malignant tumors of other systems, c: patients who lost follow-up
a study comparing two forms of didanosine in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if the coated-capsule form of didanosine (ddi) is as safe and absorbed by the body as well as the chewable-tablet form of ddi. didanosine (ddi) is an anti-hiv drug. the effectiveness of ddi can be lowered by acid in the stomach. to prevent this, patients take antacids with ddi. the coated-capsule form of ddi may replace the need for antacids.

didanosine, a purine nucleoside analogue, is indicated for the treatment of hiv infection when antiretroviral therapy is warranted. didanosine is administered orally with antacids to protect it against acid-induced hydrolysis in the stomach. to eliminate the need for using buffers in the ddi formulations, an enteric-coated bead formulation of ddi is being developed. patients are randomized to 1 of 2 groups to receive treatment on 2 separate occasions at least 72 hours apart. group 1 receives the reference formulation of ddi. group 2 receives the test formulation of ddi. clinical evaluations, including clinical laboratory tests, are performed periodically during the study and at discharge. serial blood samples are collected at specific time points over the 12 hours following dosing, and are used for the pharmacokinetic variables cmax and auc(inf). factors used in analysis are sequence, subject within sequence, period, and formulation. safety is assessed by monitoring adverse effects, vital signs, ecg recordings, and clinical laboratory tests throughout the study.

Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * cd4 cell counts of at least 200 cells/mm3. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * any evidence of organ dysfunction. * any clinically significant deviations from specified baseline requirements for physical examinations, laboratory tests, or 12-lead electrocardiogram.

Keywords: didanosine tablets reverse transcriptase inhibitors anti-hiv agents therapeutic equivalency
patient-directed antimicrobial duration in acute uncomplicated pyelonephritis

Conditions: Pyelonephritis Acute

Summary: this pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (pdad). the primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.

following informed consent, patients will be randomized to receive 10 days of cephalexin or pdad (minimum of 3 days of cephalexin followed by placebo once patient reports 24 hours of symptom resolution). patients will be evaluated at day 1 in-person, then daily using a mobile cellphone application to assess acute uncomplicated pyelonephritis (aup) symptoms and quality of life (qol). urine samples will be collected at in-person visits at day 1, 3 weeks, and 4 weeks. study feasibility will be assessed through day 90.

Eligibility criteria:
inclusion: * females between 18 and 55 years of age * diagnosis of acute uncomplicated pyelonephritis * can be discharged home on oral antimicrobial treatment * ability to provide written informed consent in english or spanish exclusion: * took antibiotics in the prior 48 hours * insulin-dependent diabetes * end-stage liver disease * if the patient reports a penicillin allergy, and is deemed to be high-risk using the penicillin allergy clinical decision rule (pen-fast) * serious allergy (e.g., angioedema, anaphylaxis) to the study medication or a similarly reported allergy to a cephalosporin * known or identified hydronephrosis, obstruction, or abscess identified by emergency department ultrasound * presence of a kidney stone * pregnancy or lactation * renal dysfunction (defined as creatinine clearance of less than 30 ml/min) * renal transplantation * complicated pyelonephritis (defined anatomical or functional abnormality of the urinary tract that predisposes to infection) * need for additional antimicrobial therapy for a coexisting infection * human immunodeficiency virus (hiv) infection, with either a recent (in the past 6 months) acquired immune deficiency syndrome-defining condition or a cluster of differentiation-4 (cd-4+) t lymphocyte count \<200/mm\^3

Keywords: cephalexin
moxibustion for knee osteoarthritis

Conditions: Idiopathic Osteoarthritis

Summary: this study aims to assess the feasibility, effectiveness and safety of moxibustion for symptom management and function improvement in patients with knee osteoarthritis, compared to usual care group.

knee osteoarthritis (oa) is a common joint disease and a leading cause of pain and physical disability in older people. its symptoms, including pain and physical disability, significantly affect patient's quality of life, and increased depression has been observed in patients with greater pain due to knee oa. current management options include exercise, weight reduction, non-steroidal anti-inflammatory drugs (nsaids) and other pain medication, intra-articular injections of steroid or hyaluronan, arthroscopic surgery and joint replacement. except exercise and weight reduction, no known interventions have shown definitive evidence of benefits and safety for knee oa. thus, it is still worth exploring effective and safe management options for knee oa patients. moxibustion is one of traditional asian medicine using the heat stimulation by burning mugwort (mainly artemisia vulgaris or artemisia argyi) on acupuncture points, and regarded as a subtype of acupuncture. previous literatures reported its use on chronic conditions including gastrointestinal disease, hypertension, musculoskeletal pain, cancer care, gynecological conditions and stroke rehabilitation solely or in combination with routine care or other traditional medicine. however, studies adequately evaluating effects and safety of moxibustion for patients with knee oa are insufficient. given the gaps between little evidence for effects and safety of moxibustion for knee osteoarthritis and its wide use in clinical practice, the investigators attempted to assess the feasibility, effectiveness and safety of moxibustion for patients with knee osteoarthritis.

Eligibility criteria:
inclusion criteria: * aged from 40 to 70 years old * average daily knee pain over 40 points (0-100 point scale) * diagnosed as knee osteoarthritis according to acr criteria exclusion criteria: * current of past history of inflammatory disease including rheumatoid arthritis * cancer * traumatic injury which might be related to current knee pain * autoimmune disease * significant deformity of knee joints * knee replacement surgery on affected knee * knee arthroscopy within 2 years * steroid injection in knee joints within 3 months * viscosupplement injections in knee joints within 6 months * joint fluid injection within 6 months * received acupuncture, moxibustion, cupping or herbal medicine within 4 weeks * uncontrolled hypertension * diabetes mellitus requiring insulin injection * life-threatening cardiovascular or neurological events within one year * chronic respiratory disease * hemorrhagic disorder * alcohol or drug addition * active infectious disease including tuberculosis * keloidosis

Keywords: knee osteoarthritis
acupuncture for breast engorgement during lactation

Conditions: Breast Engorgement

Summary: breast engorgement which may manifest swell, throb, and cause mild to extreme pain is the common difficulty for breast feeding woman. it occurs in the mammary glands due to expansion and pressure exerted by the synthesis and storage of breast milk and it usually happens when the breasts switch from colostrums to mature milk. however, engorgement can also happen if lactating women miss several nursing and not enough milk is expressed from the breasts. it can be exacerbated by insufficient breastfeeding and/or blocked milk ducts. engorgement may lead to mastitis and untreated engorgement puts pressure on the milk ducts, often causing a plugged duct. according the meridian theory, the investigators propose the acupuncture treatment for patients of breast engorgement. the investigators will include 60 patients and measure the acupuncture effect. the inclusion criteria are women with breast engorgement and 20 years old or older. exclusion standards are patients with: 1. diabetes mellitus 2. psychological disease or mental illness 3. fever \> 38 degrees celsius 4. mastitis 5.analgetics or anti - inflammatory agents used 6. ultrasound therapy applied


Eligibility criteria:
inclusion criteria: * women with breast engorgement and 20 years old or older exclusion criteria: * patients with: 1. diabetes mellitus 2. psychological disease or mental illness 3. fever \> 38 degrees celsius 4. mastitis 5. analgesics or anti - inflammatory agents used 6. ultrasound therapy applied

Keywords: acupuncture breast engorgement lactation
the influence of rapid recovery on sleep quality following total knee replacement surgery

Conditions: Arthroplasty, Replacement, Knee; Recovery of Function; Arthritis, Rheumatoid

Summary: the purpose of this study is to evaluate the influence of rapid recovery on sleep quality following total knee replacement surgery.


Eligibility criteria:
inclusion criteria: 1. primary unilateral total knee artropasty; 2. patients with knee osteoartritis or rheumatoid arthritis; 3. able and willing to provide signed informed consent. exclusion criteria: 1. simultaneously bilateral total knee artropasty or revision case; 2. surgical history of the knee joint; 3. knee joint cavity paracentesis in recent 3 months; 4. stiffness with knee; 5. blood coagulation disorders; 6. history of deep venous thrombosis; 7. concomitant medical problems such as uncontrolled hypertention, severe cardiovascular disorder, chronic obstructive pulmonary disease, liver or renal failure 8. allergic to nsaids, opioid analgesics, zolpidem 9. sleep apnea, parkinson disease, dementia, depression 10. use of sedatives or hypnotics 11. inability to comply with polysomnographic measurement
quality of life in adult patients with severe haemophilia in turkey

Conditions: Haemophilia

Summary: the primary aim of this study is to evaluate the overall quality of life in adult patients with severe haemophilia (an inherited bleeding disorder affecting mainly men) in turkey and to assess the impact of certain disease and drug related factors (treatment modality, presence of viral disease, inhibitor, etc.) on the quality of life.

haemophilia is an inherited bleeding disorder affecting one in 10000 male births worldwide. people with severe haemophilia usually suffer from recurrent life threatening bleeds (e.g. into the brain, digestive system or abdomen) and/or disabling degenerative disease of weight bearing joints (e.g. knees, elbows and ankles)resulting from haemorrhage into the joints. daily activities of people with haemophilia has been shown to be dramatically hampered by the resultant joint damage. evaluation of quality of life issues in people with severe haemophilia would help to create awareness of their problems and limitations. this would also set up the scene for developing policies to improve the treatment options/facilities and social life of the patients. current study aims to assess the quality of life of adult patients with severe haemophilia in a developing country (turkey) by using a validated quality of life questionnaire (turkish version of haem-a-qol).

Eligibility criteria:
inclusion criteria: * age equal or greater than 18 years * male gender * factor viii or ix level equal or below 1% * patients that are willing to participate and have given a written consent exclusion criteria: * age less than 18 years * females * factor levels above 1%

Keywords: severe haemophilia quality of life